These data indicate that the activation of EPHA3 with ephrin-A5 pharmaceutical analogues could be a future chemotherapeutic strategy to suppress the motile and metastatic phenotype of tumor cells in rhabdomyosarcoma patients. The gene discussed is EPHA3; the disease is neoplasm.